Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trialAnders Widmark, Sophie D. Fosså|The Lancet|2008Cited by 873
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term SurvivorsLois B. Travis, Ethel S. Gilbert, Sophie D. Fosså et al.|JNCI Journal of the National Cancer Institute|2005Cited by 830
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924Cora N. Sternberg, Laurence Collette, A.T. van Oosterom et al.|Journal of Clinical Oncology|2001Cited by 628
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Christopher Parker, Robert L. Coleman et al.|The Lancet Oncology|2014Cited by 491
Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's LymphomaDavid Hodgson, Lois B. Travis, Ethel S. Gilbert et al.|Journal of Clinical Oncology|2007Cited by 348